No currently licensed and available vaccine has been shown to provide broad protection against endemic MnB disease.
Prime Ministers of Australia and New Zealand have agreed to provide $3M to help fast-track the development of a vaccine against rheumatic fever.
The desire for an effective vaccine arises from the large burden of disease caused by the bacterium, particularly rheumatic fever and rheumatic heart…
Vaccination is the most effective strategy for preventing influenza infection in pregnancy.
We conducted an open randomized controlled trial in Papua New Guinea to compare safety, immunogenicity and priming for memory of 7-valent PCV (PCV7)…
Common myths about immunisation have been laid to rest in a new booklet written by top immunologists and published by the Australian Academy of Scien…
A bivalent, recombinant, factor H-binding protein (rLP2086) vaccine was developed to protect against invasive Neisseria meningitidis serogroup B (MnB…
Despite an effective vaccine, measles remains a major health problem globally, particularly in developing countries. More than 30% of children show p…
Neisseria meningitidis is a leading cause of meningitis and septicaemia, but a broadly-protective vaccine against endemic serogroup B disease is not…
A pooled analysis was conducted of 1,257 toddlers who received a fourth dose of Haemophilus influenzae type b- Neisseria meningitidis serogroups C an…